Literature DB >> 7044595

VM26: phase I and II studies.

F R Macbeth.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 7044595     DOI： 10.1007/bf00254527

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  29 in total

1.  VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.

Authors:  M K Samson; L H Baker; R W Talley; R J Fraile
Journal:  Eur J Cancer       Date:  1978-12       Impact factor: 9.162

2.  Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.

Authors:  J G Rosenstock; M H Donaldson
Journal:  Cancer Treat Rep       Date:  1976-03

3.  Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.

Authors:  N M Gad-el-Mawla; F M Muggia; M R Hamza; B El-Morsi; M Sherif; M A Mansour; M Khafagy; I T El-Sebai
Journal:  Cancer Treat Rep       Date:  1978-07

4.  VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).

Authors:  D F Chiuten; J M Bennett; R H Creech; J Glick; G Falkson; H S Brodovsky; C B Begg; F M Muggia; P P Carbone
Journal:  Cancer Treat Rep       Date:  1979-01

Review 5.  VM 26 and VP 16-213: a comparative analysis.

Authors:  M Rozencweig; D D Von Hoff; J E Henney; F M Muggia
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

6.  Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.

Authors:  G Mathé; L Schwarzenberg; P Pouillart; R Oldham; R Weiner; C Jasmin; C Rosenfeld; M Hayat; J L Misset; M Musset; M Schneider; J L Amiel; F De Vassal
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

7.  Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.

Authors:  B D Sklansky; R S Mann-Kaplan; A F Reynolds; M L Rosenblum; M D Walker
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

8.  Use of VM-26 as a single agent in the treatment of renal carcinoma.

Authors:  E A Hire; M K Samson; R J Fraile; L H Baker
Journal:  Cancer Clin Trials       Date:  1979

Review 9.  Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.

Authors:  M L Gutierrez; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-09       Impact factor: 12.111

10.  Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study.

Authors: 
Journal:  Eur Urol       Date:  1976       Impact factor: 20.096
View more
  1 in total

Review 1.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.